Hidden health risks: What your bra could be doing to your body
Bras are pesky, uncomfortable, and — if you've got sensory issues like me — downright irritating.
But it turns out they can be causing serious damage, too.
Preventing you from breathing properly, standing tall, and even feeling calm. Yikes.
From pinched nerves to posture problems, scientists and bra-fitters alike are spilling the boob tea.
The wrong bra (and sometimes any bra) can be a total health saboteur. And yes, this includes the holy sports bra.
Before you start a bonfire to burn all your bras for good, here's what can be causing issues, and how to fix them.
First, let's address the urban legend. Bras do not cause breast cancer.
There's evidence, including a population-based case-control study of postmenopausal women, found no link between bra wearing and cancer risk.
That's regardless of underwire or hours worn.
Now, strap in. Here's the ugly truth about what's lying under your T-shirt.
Neck, shoulder and back pain
Those trenches in your shoulders aren't just annoying, they're bad news.
Deep grooves and red marks are signs your shoulders are carrying way too much weight.
For women with a D-cup or larger, each breast can weigh 1.3kg or more.
So, a bad fit turns into a literal load on your neck and spine, leading to poor posture, neck and back pain, tension headaches and long-term spinal misalignment.
Clinical reports even cite narrow, tight straps from heavy-breasted women causing nerve and blood vessel compression in the clavicle area, a condition nicknamed 'bra strap syndrome.'
Breathing and lymph flow restrictions
Underwires and overly snug bands don't just squish your boobs.
They can compress your rib cage, making it harder to breathe deeply, and can slow lymphatic drainage, the body's natural waste-removal system.
Some experts also flag the use of nickel, latex, and BPA in bra materials as potential skin irritants and allergens.
Anxiety and shallow breathing
One lingerie designer warns that bra-induced shallow breathing can trigger the body's stress response, leaving you feeling tense without realising why.
That tight band isn't just cutting off your comfort, it could literally be cutting into your calm.
'Wearing something that hurts or digs or reminds you all day long that your body doesn't fit the mould … and that takes a toll,' Bree McKeen told New York Post.
'The discomfort can be distracting, exhausting, even demoralising.'
Worst offender: The underwire push-up
It's the one most of us have owned at least once, and according to McKeen, it's the style doing the most damage.
The underwire push-up bra pushes breast tissue into unnatural shapes, digs into delicate areas, compresses lymph pathways, and sets the stage for skin irritation and scarring.
That perky lift could be costing you your long-term comfort.
Even sports bras have a dark side
Sure, they're great for high-impact workouts, but a University of Portsmouth study found overly restrictive sports bras can shift too much load to the spine, forcing back muscles to overcompensate.
Over time, that can lead to serious back pain and strain.
So, are there proven benefits to going braless?
A 15-year French study tracked 330 women aged 18–35 and found those who went braless saw firmer, perkier breasts (around 7mm of nipple lift per year), better posture, deeper breathing, and less back pain. Sign, Me. Up.
Researchers also suggested bras may weaken natural muscle support over time.
Critics did point out the study's sample wasn't representative and factors like pregnancy weren't accounted for.
But it still challenges the long-held belief that constant strapping equals better support.
Now, for the large-bust crew reading this, I'm sure you're rolling your eyes. And your scepticism is valid.
If your daily reality includes heavier breasts pulling your spine into a permanent hunch, going braless might sound like a sick joke. Here's the nuance:
Support can help initially: If you've relied on bras for decades, quitting cold turkey may worsen posture or pain at first. Experts recommend gradually reducing wear while strengthening upper-back and chest muscles.
Fit is everything: Around 80–85 per cent of women wear the wrong bra size, which means the band rides up your back, straps do all the heavy lifting, and pain piles on.
Better strap design matters: Wide, vertical straps (around 4.5 cm) or gel-padded options have been shown to reduce shoulder pressure during activity.
So … do you torch all of your bras now?
Not necessarily. The villain is bad fit and over-reliance, not every bra ever made.
Choose breathable fabrics, adjustable straps, and proper measurements.
If you're feeling up to it, go braless when you can. especially at home.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
ABC News
2 hours ago
- ABC News
Queensland premier, deputy premier refuse to publicly share flu vaccination status amid low uptake
Queensland's deputy premier says he is comfortable with the state's flu vaccination rates, despite an expert warning they are among the lowest in the country. Infectious diseases physician Paul Griffin said it was "clear" not enough people were receiving the jab, with the latest data showing about 4,000 influenza cases had been reported locally in a week. "We have seen a lot of admissions to hospital ... and that is probably partly related to a low vaccination rate," he said. In June, Health Minister Tim Nicholls announced a 48-hour pause on elective surgeries at Queensland's largest hospitals on account of them being overwhelmed by patients with the flu and COVID-19. At the time, Mr Nicholls urged Queenslanders to "get the vaccine now". When asked on Tuesday whether he had been vaccinated this year, Deputy Premier Jarrod Bleijie said that was a "private matter between me and my doctor". His response mirrored Premier David Crisafulli who on Monday said of his flu vaccination status: "That is between me and my doctor". "We're not going to be a government, like former governments, dictating what people do in their own homes, their own lives or with their doctors," Mr Bleijie said. "If people want to get the flu vaccination they are entitled to do that, I'm not going to dictate whether they should do it or not. "We will deal with the influx of people in the hospitals, just as the health minister has been doing, with our wonderful doctors and nurses on the frontline." According to Queensland Health, the state recorded 106 flu-related deaths this year up until August 3, which is 12 more than in the same period last year. Health department data showed fewer than one-third of Queenslanders have had their flu jab in 2025, although there had been a notable increase in vaccination uptake earlier this month. Professor Griffin said while he understood not everyone wanted to be vaccinated on-camera, a leader saying whether they had received the jab was "something that could be done". 'I think people in positions of power sharing that they are also onboard with the messaging that our health department is sharing is something that could really be important,' he said. Shadow Health Minister Mark Bailey said Mr Crisafulli and Mr Bleijie were "failing the leadership test" by refusing to say publicly whether they had received the flu vaccination. "How can they expect Queenslanders to go out there and ensure that they are protected if they themselves are not willing to simply share that information?" he said. Mr Crisafulli, in response to criticism, has said his government had restored free flu vaccinations that were not funded, spent more money on advertising flu jabs than last year and started the vaccination program rollout earlier than in previous years. Queensland Health data showed year-to-date cases were down 2 per cent on last year's. Mr Crisafulli said this was a 'reasonable indication of how seriously' the government was taking the flu season. Mr Bailey said it was "curious" that Mr Crisafulli and Mr Bleijie had previously promoted receiving the COVID-19 and flu vaccinations but were now not willing to say publicly whether they had been vaccinated. "I think what is pretty clear is that you are seeing [them] play to the anti-vax crowd," Mr Bailey said. Mr Bleijie said his position on vaccination had not changed and rejected the idea his stance was an attempt to appeal to voters who had anti-vaccination views. "We have a campaign on the flu vaccinations, but the health of Queenslanders is a matter for Queenslanders with individual responsibility," he said
News.com.au
11 hours ago
- News.com.au
FDA Waiting Room: For Aussie applicants, it's (mainly) business as usual
Despite myriad pressures under the Trump regime, the FDA's drug and device approval process largely has been unfettered Telix Pharmaceuticals expects a company-making approval decision by the end of the month Painchek is among a string of device plays awaiting the agency's assent The US Food & Drug Administration's (FDA) resources have been cut more times than Martin Scorsese's then-edgy 1988 religious drama The Last Temptation of Christ. Word from within the powerful agency's imposing Maryland portals is that reviewers have struggled with their task of late because of lack of access to Zoom calls and similar everyday privations. For a legion of Australian drug and device makers awaiting company-making FDA approvals, it's a nervous time. But need they be worried? Business as usual In most cases, the risk of rejection is the same as being struck by lightning. The prevailing message is that despite mayhem at the agency in the Trump era, the approval process has not overly slowed unless the therapy is in a controversial realm (read: vaccines). Rather like the Kyiv denizens carrying out their lives amid a barrage of missiles, it's largely business as usual. A couple of notable rejections aside – namely Replimune Group's melanoma drug RP1, and see the Telix section below – so far this year the FDA has approved therapies for a range of cancers, autoimmune diseases, urinary tract infections and even menopausal hot flushes. PainChek (ASX:PCK) CEO Phil Daffas says the FDA does a 'superb' job under considerable pressure. The developer of a digital pain assessment, Painchek awaits FDA clearance under the de novo (new) device pathway (see below). 'Their M.O. (modus operandi) has been nothing but guidance and support,' he says. Aussie biotechs get the nod ASX life science have-a-go heroes have found favour, especially in the devices and diagnostics realm. In the drug space, the FDA last December greenlit Mesoblast's (ASX:MSB) graft-versus-host disease stem cell treatment, Ryoncil. In June, the agency approved CSL's (ASX:CSL) home-grown Andembry, the world's only prophylactic for hereditary angioedema. Device-wise, the agency approved Orthocell's (ASX:OCC) peripheral nerve repair tool Remplir. It also waved through EBR Systems' (ASX:EBR) groundbreaking left-ventricle assist device Wise and Nanosonics' (ASX:NAN) next-gen medical probe steriliser, Coris. 'Everyone was getting nervous towards the end, but we were very fortunate not to be impacted (by the FDA changes),' Nanosonics chief Michael Kavanagh says. 'The Australian medtech industry should be proud, not necessarily Nanosonics but Australia's ability to do these types of things.' Telix sweats on kidney imaging decision Is the FDA poised to make us further proud? Radiopharmacy giant Telix Pharmaceuticals (ASX:TLX) will know within three weeks whether the FDA has approved its kidney cancer imaging agent, Zircaix. The stakes could not be higher for the $6.8 billion market cap Telix, given Zircaix could well present a bigger market than for Illuccix, its approved prostate cancer imaging agent. So far at least, the FDA hasn't come back with any queries. Mind you, Telix hasn't had its way on other fronts. The FDA in late April knocked back the company's New Drug Application (NDA) for its brain cancer imaging agent, TLX101-CDx. As Telix CEO Dr Chris Behrenbruch pointedly noted, this was despite 'a robust consultation process prior to submission and during review of the NDA'. Painchek's painless process As with Telix, the FDA's decision will be company making for Painchek. Painchek's eponymous app is used across 110,000 nursing home beds in Australia, the UK and Canada – an addressable market of 500,000 beds. The US opens a market of three million beds, worth an estimated $100 million in annual recurring revenue. Painchek's FDA process started in 2019, when the company sought guidance on a supportive clinical trial (since successfully completed). 'The primary contact was the same person all the way through,' Daffas says. Painchek lodged its review in November 2024, after two pre-submission meetings with the agency. 'They recommended a two-step process, with feedback after each step,' he says. 'That was very helpful guidance. If there was room for a misunderstanding it got clarified in those two meetings.' Daffas says the FDA reps included experts in AI, privacy rules and cybersecurity and communications. 'Once again it's very helpful for us, as it makes for a more robust product.' Painchek expects an FDA decision around early October. 4D Medical breathes easy The developer of algo-based lung images tools, 4D Medical (ASX:4DX), has 'frequent flyer' status with the FDA which has approved eight of its devices already. These include its XV LVAS, which processes conventional X-ray scans 'to provide rich, functional lung health detail not available via other modalities'. 4D is now waiting to hear from the FDA about a ventilation perfusion imaging device. The company dubs the FDA's review as 'well progressed'. 4D has filed under the 510(k) predicate device route. According to the company, last year companies waited an average 112 days for an FDA yeah or nay. The current situation is 'aligning well with our experience in previous applications', the company says. Artrya is back for seconds … Artrya (ASX:AYA) says hard-to-detect coronary plaque is a key cause of heart attacks. This was an uncontroversial proposition for the FDA, which in late March approved Artrya's Salix Coronary Anatomy (SCA) platform. The AI-enabled tool provides point-of-care detection of high-risk plaque, a key predictor of heart attacks. Artrya has submitted for approval of a second device, Salix Coronary Plaque (SCP). SCP will extend the use to patients who have undergone a coronary CT angiogram. 'Once cleared, will enable us to deliver near real-time, AI-powered cardiac analysis to a large and growing market and unlock access to an established reimbursement code for plaque analysis,' co-founder (and now CEO) John Konstantopoulos says. The company expects to hear from the FDA by the end of September. … as is Echo IQ As with Artrya, heart diagnosis peer Echo IQ (ASX:EIQ) is no stranger to the FDA. In October last year the agency approved its EchoSolv AS, an AI-inspired device to detect aortic stenosis (narrowing of the heart valves). Echo IQ now is eyeing consent for a second product, EchoSolv HF, to detect heart problems early. It has teamed up with the esteemed Mayo Clinic to carry out a validation trial, the final requirement for FDA submission. Mayo also has exclusive rights to use EchoSolv HF across its 30 hospitals and possibly even co-brand the product. Echo IQ expects FDA approval by the end of the year. Imricor goes modular Still on matters of the heart, Imricor Medical Systems (ASX:IMR) is taking a Lego Masters approach to its maiden FDA application, for its cardiac ablation device, Vision-MR. By this we mean that Imricor has submitted its FDA in separate modules ('bricks'), to enable a rolling review. Vision-MR is the only ablation catheter designed for use with a magnetic resonance imaging (MRI) scanner, as opposed to x-ray fluoroscopy. The company last week said the second module was under review and it expects to submit the third module in the December quarter. 'We expect a steady string of 510(k) product submissions and approvals, which in turn helps accelerate the commercial launch across the US," the company says. In the March quarter European regulators re-approved Vision-MR, under tougher new rules. The European gatekeepers also approved Northstar, 'the world's only MRI-native 3D mapping and guidance system.' The FDA is also likely to approve Northstar in the current half. This will enable the company to start the initial rollout of its interventional cardiac magnetic resonance cardiac ablation labs. Patience, please Some applicants strike trouble with the FDA because they assume that reading the agency's intentions is easy as a Golden Book, when in fact they can be harder to fathom than Ulysses. As Telix's brain cancer setback attests, being on the same page is crucial. Amid the chaos of RFK Jr's early days as health czar, in March your columnist warned that while FDA approvals were often company making, don't expect quick returns. That's because shares may have run hard in anticipation of the happy event and profit takers move in. Often, companies raise capital on positive news and this constrains the share price. EBR did the rounds for $66 million in May and Mesoblast in January raised a monstrous $260 million. FDA approval is only the first step to commercialisation: securing reimbursement and distribution network are just as important. But without consent, companies aren't even in the starting block to tackle the world's richest – albeit more quixotic – healthcare market. If anyone needs reminding, the US accounts for roughly half of the world's healthcare expenditure.
ABC News
21 hours ago
- ABC News
How the United States found itself in a measles 'crisis'
There is a high risk the US will lose its measles elimination status — that's the stark warning from the country's health experts. The viral outbreak has led to broader questions over radical changes in vaccine policy under the leadership of Health Secretary Robert F Kennedy Jr. North America correspondent Kamin Gock reports.
